Advertisement

FDA approves glecaprevir-pibrentasvir for HCV

Share This Page
FDA approved on Thursday glecaprevir–pibrentasvir (Mavyret—AbbVie) for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis.

FDA approved on Thursday glecaprevir–pibrentasvir (Mavyret—AbbVie) for the treatment of adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. The combination drug is also approved for adult patients with HCV genotype 1 infection who have been previously treated with a regimen either containing an NS5A inhibitor or an NS3/4A protease inhibitor but not both. This is the first treatment of 8 weeks duration approved for all HCV genotypes 1-6 in adults without cirrhosis who have not been previously treated. The standard treatment length was previously 12 weeks or more. "This approval provides a shorter treatment duration for many patients, and also a treatment option for certain patients with genotype 1 infection, the most common HCV genotype in the United States, who were not successfully treated with other direct-acting antiviral treatments in the past," said Edward Cox, MD, director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. Clinical trials involving about 2,300 adults with HCV genotype 1, 2, 3, 4, 5, or 6 without cirrhosis or with mild cirrhosis found that 92%–100% of patients who received glecaprevir–pibrentasvir for 8, 12, or 16 weeks duration had no detectable virus in their blood 12 weeks after treatment completion. Treatment duration with glecaprevir–pibrentasvir varies depending on treatment history, viral genotype, and cirrhosis status. The most frequently reported adverse reactions in patients taking glecaprevir–pibrentasvir were headache, fatigue, and nausea. Glecaprevir–pibrentasvir is not recommended in patients with moderate cirrhosis and contraindicated in patients with severe cirrhosis. It is also contraindicated in patients taking atazanavir and rifampin.

Ad Position: 
Bottom Center Aligned
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm

Advertisement

Related Content

block-views-related-content-block